This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
Earnings Growth & Price Strength Make UnitedHealth Group (UNH) a Stock to Watch
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
UnitedHealth Group (UNH) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
UnitedHealth Group (UNH) closed at $587.13 in the latest trading session, marking a +0.45% move from the prior day.
UnitedHealth (UNH) Rises 15% in 3 Months: Jump in or Wait out?
by Kaibalya Pravo Dey
UnitedHealth's (UNH) expansion into targeted markets, strategic diversification and attractive dividends present significant growth opportunities.
Take the Zacks Approach to Beat the Markets: Vista Gold, TransMedics, Accenture in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Why Is Molina (MOH) Up 6.1% Since Last Earnings Report?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
UnitedHealth Group (UNH) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here is What to Know Beyond Why UnitedHealth Group Incorporated (UNH) is a Trending Stock
by Zacks Equity Research
UnitedHealth (UNH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Here's Why UnitedHealth Group (UNH) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, UnitedHealth Group (UNH) stood at $578.78, denoting a +0.19% change from the preceding trading day.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Why UnitedHealth Group (UNH) is a Top Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
Why Is UnitedHealth (UNH) Up 1.1% Since Last Earnings Report?
by Zacks Equity Research
UnitedHealth (UNH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Markets Mixed Ahead of Key Inflation Data
by Mark Vickery
Tomorrow morning, the Producer Price Index (PPI) will demonstrate levels of wholesale inflation.
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
by Zacks Equity Research
Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.
Why UnitedHealth Group (UNH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Invesco S&P 500 Revenue ETF (RWL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RWL
Pediatrix (MD) Q2 Earnings Top on Stable Volumes, Shares Up 7.4%
by Zacks Equity Research
Pediatrix's (MD) second-quarter earnings benefit from stable patient volumes. Rising expenses act as a partial offset.
Is Trending Stock UnitedHealth Group Incorporated (UNH) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to UnitedHealth (UNH). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Select Medical's (SEM) Stock Down 16.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) expects its adjusted EBITDA between $845 million and $885 million for 2024, the mid-point of which implies a 7.1% rise from the 2023 reported figure of $807.4 million.
Earnings Growth & Price Strength Make UnitedHealth Group (UNH) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Beat the Market Like Zacks: Motorola, UnitedHealth, Virtu in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Should SPDR Dow Jones Industrial Average ETF (DIA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DIA
Teladoc Health (TDOC) Shares Down 8.9% Despite Q2 Earnings Beat
by Zacks Equity Research
Teladoc Health (TDOC) expects revenue growth in the Integrated Care segment to be within low to mid-single-digit growth in 2024, on a year-over-year basis.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Cigna (CI) Q2 Earnings Top on Specialty Business Strength
by Zacks Equity Research
Cigna's (CI) Q2 results reflect new client wins in the Evernorth Health Services unit, partly offset by elevated pharmacy costs. It continues to expect adjusted EPS of at least $28.40 for 2024.